Medical device company Apyx Medical Corporation (NASDAQ:APYX) stated on Monday that it expects total revenue in a range of USD16.3 to USD16.8m for the fourth quarter ended 31 December 2021.
This marks a growth of 42% to 46% in total revenues year-over-year.
For the fourth quarter ended 31 December 2021, the company anticipates Advanced Energy revenue in the USD14.7 to USD15.0m range, representing growth of 49% to 52% year-over-year. OEM revenue in the USD1.5 to USD1.7m range, down 2% year-over-year to growth of 10% year-over-year.
The company expects total revenue in a range of USD48.0 to USD48.5m for the full year 2021, a rise of 73% to 75% year-over-year.
In addition, the company expects Advanced Energy revenue in a range of USD42.7 to USD43.0m, an increase of approximately 92% to 93% year-over-year. OEM revenue in a range of USD5.3 to USD5.5m, a dip of 4% to 0% year-over-year.
TELA Bio launches LIQUIFIX for US hernia surgery
Cognizant and NVIDIA partner to revolutionize drug discovery with generative AI
Neupulse raises funds for Tourettes Syndrome wearable tech
Bonesupport gains FDA clearance for CERAMENT G in open fractures
Epitomee submits Weight Loss Capsule for FDA approval in US
Halma acquires Rovers Medical Devices
boston Scientific granted FDA approval for AGENT Drug-Coated Balloon